Mesenchymal Stromal Cells for Graft Versus Host Disease: Mechanism-Based Biomarkers.

ABSTRACT: The immunosuppressive activity of mesenchymal stromal cells (MSCs) in graft versus host disease (GvHD) is well-documented, but their therapeutic benefit is rather unpredictable. Prospective randomized clinical trials remain the only means to address MSC clinical efficacy. However, the imperfect understanding of MSC biological mechanisms has undermined patients' stratification and the successful design of clinical studies. Furthermore, although MSC efficacy seems to be dependent on patient-associated factors, the role of patients' signature to predict and/or monitor clinical outcomes remains poorly elucidated. The analysis of GvHD patient serum has identified a set of molecules that are associated with high mortality. However, despite their importance in defining GvHD severity, their role i

SUBMITTER: Cheung TS 

PROVIDER: S-EPMC7330053 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature